Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter


IMPACT FACTOR 2018: 3.638

CiteScore 2018: 2.44

SCImago Journal Rank (SJR) 2018: 1.191
Source Normalized Impact per Paper (SNIP) 2018: 1.205

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 48, Issue 12

Issues

Relationship of hepatic steatosis and alanine aminotransferase with coronary calcification

Dong-Hyuk Jung / Yong-Jae Lee / Hong-Yup Ahn / Jae-Yong Shim / Hye-Ree Lee
Published Online: 2010-10-20 | DOI: https://doi.org/10.1515/CCLM.2010.349

Abstract

Background: It has been observed that hepatic steatosis is related to an increased risk of cardiovascular disease (CVD). Alanine aminotransferase (ALT), an indicator of the severity of hepatic steatosis is also associated with CVD. This study focused on the relationship between hepatic steatosis and ALT with coronary calcification.

Methods: We performed a cross-sectional study to examine the association between hepatic steatosis and serum ALT with coronary calcification in 1218 subjects (772 men, 446 women; ages 30–75 years). We evaluated hepatic steatosis and ALT as categorical variables, and constructed four groups (reference group; only with hepatic steatosis; only with ALT >30 U/L; with both hepatic steatosis and ALT >30 U/L), which did not overlap. Multi-detected row computed tomography (MDCT) was used to measure coronary calcium score.

Results: The adjusted ORs (95% CIs) for coronary calcification in the four groups were 1.00 (reference), 1.24 (0.68–2.26), 1.82 (0.78–4.23), and 2.12 (1.08–4.20) after adjusting for confounding variables. In addition, an increase in serum ALT activity of 10 U/L was associated with an increased risk of coronary atherosclerosis.

Conclusions: In summary, patients with both hepatic steatosis and increases in ALT are associated with coronary calcification as a marker of coronary atherosclerosis determined by MDCT. This finding suggested that subjects with both hepatic steatosis and increased ALT should be considered for further evaluation of coronary atherosclerosis.

Clin Chem Lab Med 2010;48:1829–34.

Keywords: alanine aminotransferase; coronary calcification; hepatic steatosis

About the article

Corresponding author: Hye-Ree Lee, MD, PhD, Professor, Department of Family Medicine, Yonsei University College of Medicine, 146-92 Dogok-dong, Gangnam-gu, Seoul, Korea Phone: +82 2-2019-3484, Fax: +82 2-3463-3287,


Received: 2010-02-10

Accepted: 2010-06-24

Published Online: 2010-10-20

Published in Print: 2010-12-01


Citation Information: Clinical Chemistry and Laboratory Medicine, Volume 48, Issue 12, Pages 1829–1834, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2010.349.

Export Citation

©2010 by Walter de Gruyter Berlin New York.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Devika Kapuria, Varun K. Takyar, Ohad Etzion, Pallavi Surana, James H. O'Keefe, and Christopher Koh
Hepatology Communications, 2018
[2]
Veeravich Jaruvongvanich, Kamonkiat Wirunsawanya, Anawin Sanguankeo, and Sikarin Upala
Digestive and Liver Disease, 2016, Volume 48, Number 12, Page 1410
[3]
Byung Jin Kim, Eun Sun Cheong, Jung Gyu Kang, Bum Soo Kim, and Jin Ho Kang
Journal of Clinical Lipidology, 2016, Volume 10, Number 3, Page 619
[4]
Kathleen Jacobs, Sharon Brouha, Ricki Bettencourt, Elizabeth Barrett-Connor, Claude Sirlin, and Rohit Loomba
Clinical Gastroenterology and Hepatology, 2016, Volume 14, Number 9, Page 1337
[5]
Mariana Lazo, Jonathan Rubin, Jeanne M. Clark, Josef Coresh, Andrea L.C. Schneider, Chiadi Ndumele, Ron C. Hoogeveen, Christie M. Ballantyne, and Elizabeth Selvin
Journal of Hepatology, 2015, Volume 62, Number 4, Page 841
[6]
K.-C. Sung, S. H. Wild, H. J. Kwag, and C. D. Byrne
Diabetes Care, 2012, Volume 35, Number 11, Page 2359
[7]
Abbas Arjmand
Iranian Red Crescent Medical Journal, 2013, Volume 15, Number 12
[8]
Rajiv Chhabra, James H. O’Keefe, Harshal Patil, Evan O’Keefe, Randall C. Thompson, Shaya Ansari, Kevin F. Kennedy, Linda W. Lee, and John H. Helzberg
Mayo Clinic Proceedings, 2013, Volume 88, Number 11, Page 1259
[9]
Ebenezer T. Oni, Arthur S. Agatston, Michael J. Blaha, Jonathan Fialkow, Ricardo Cury, Andrei Sposito, Raimund Erbel, Ron Blankstein, Ted Feldman, Mouaz H. Al-Mallah, Raul D. Santos, Matthew J. Budoff, and Khurram Nasir
Atherosclerosis, 2013, Volume 230, Number 2, Page 258
[10]
Consuelo P. Vilar, Helma P. Cotrim, Gesira S. Florentino, Cibelle P.V. Barreto, André Vinicius A. Florentino, Gerson Bragagnoli, and Paulo A. Schwingel
Revista da Associação Médica Brasileira, 2013, Volume 59, Number 3, Page 290
[11]
Mary F. Feitosa, Alexander P. Reiner, Mary K. Wojczynski, Mariaelisa Graff, Kari E. North, Jeffrey J. Carr, and Ingrid B. Borecki
Atherosclerosis, 2013, Volume 227, Number 2, Page 420
[12]
Tommy Pacana and Michael Fuchs
Clinics in Liver Disease, 2012, Volume 16, Number 3, Page 599
[13]
Donghee Kim, Su-Yeon Choi, Eun Ha Park, Whal Lee, Jin Hwa Kang, Won Kim, Yoon Jun Kim, Jung-Hwan Yoon, Sook Hyang Jeong, Dong Ho Lee, Hyo-suk Lee, Joseph Larson, Terry M. Therneau, and W. Ray Kim
Hepatology, 2012, Volume 56, Number 2, Page 605
[14]
Jongmin Lee
The International Journal of Cardiovascular Imaging, 2011, Volume 27, Number S1, Page 9
[15]
Giovanni Targher
Clinical Chemistry and Laboratory Medicine, 2011, Volume 49, Number 4

Comments (0)

Please log in or register to comment.
Log in